• Explore /
  • Poster
  • / A phase 1/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab for unresected, stage IIIB-IV melanoma (MASTERKEY-265).

A phase 1/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab for unresected, stage IIIB-IV melanoma (MASTERKEY-265).

Abstract Poster

Authors

Georgina Long

Georgina V. Long

Melanoma Institute Australia and The University of Sydney, North Sydney, Australia

Georgina V. Long , Reinhard Dummer , Antoni Ribas , Igor Puzanov , Olivier Michielin , Ari M. Vanderwalde , Robert Hans Ingemar Andtbacka , Jonathan S. Cebon , Eugenio Fernandez , Josep Malvehy , Anthony J. Olszanski , Thomas Gajewski , John M. Kirkwood , Olga Kuznetsova , Lisa Chen , Scott J. Diede , Jeffrey Chou , F. Stephen Hodi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02263508

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS9598)

DOI

10.1200/JCO.2016.34.15_suppl.TPS9598

Abstract #

TPS9598

Poster Bd #

199b

Abstract Disclosures

Similar Posters

First Author: Antoni Ribas

First Author: Georgina V. Long

First Author: Charlee Nardin

First Author: Diwakar Davar